Global Autoimmune Drugs Market Forecast to 2022; Led by AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer and UCB - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 7, 2019--The “Global Autoimmune Drugs Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
The autoimmune drugs market will register a CAGR of more than 8% by 2022.
High cost of autoimmune drugs to drive market growth
Governments and regulatory bodies have undertaken several initiatives to reduce the costs of therapies for autoimmune disorders mainly rheumatoid arthritis. Despite these efforts, autoimmune drugs continue to remain expensive. Biologics and biosimilars are expensive when compared with conventional therapies such as NSAIDs.
Targeted therapeutic mechanism of biologics
By providing a targeted action, biologics tend to be more effective and have lesser side effects compared with small molecule agents. Hence, the introduction of biologic therapy to manage autoimmune disorders is driving the market at a very rapid pace.
Reimbursement challenges of autoimmune drugs
The insurers are reluctant to provide reimbursement for the drugs for treatment of autoimmune diseases due to the lack of knowledge; therefore, they generally do not provide any provisions for the reimbursement of drugs for rheumatoid arthritis and other autoimmune diseases.
Key PlayersAbbVie Amgen Johnson & Johnson Novartis Pfizer UCB
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZINGMarket definition Market sizing 2017 Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
PART 08: MARKET SEGMENTATION BY THERAPY AREASegmentation by therapy area Comparison by therapy area Rheumatoid arthritis - Market size and forecast 2017-2022 Multiple sclerosis - Market size and forecast 2017-2022 Psoriasis - Market size and forecast 2017-2022 Inflammatory bowel disease - Market size and forecast 2017-2022 Others - Market size and forecast 2017-2022 Market opportunity by therapy area
PART 09: MARKET SEGMENTATION BY TYPE OF MOLECULESegmentation by type of molecule Biologics Small molecules
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPEGeographical segmentation Regional comparison Americas - Market size and forecast 2017-2022 EMEA - Market size and forecast 2017-2022 APAC - Market size and forecast 2017-2022 Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPEOverview Landscape disruption
PART 16: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors AbbVie Amgen Johnson & Johnson Novartis Pfizer UCB
For more information about this report visit https://www.researchandmarkets.com/research/5j7gz5/global_autoimmune?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190107005509/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs
KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/07/2019 06:00 AM/DISC: 01/07/2019 06:01 AM